BeyondSpring Inc. (NASDAQ:BYSI) Q2 2019 Earnings Conference Call - Final Transcript
Sep 18, 2019 • 08:00 am ET
Good day everyone and welcome to BeyondSpring Inc's Second Quarter 2019 Financial Results Conference Call. My name is Melissa and I will be the operator on today's call. Please be advised that today's call is being recorded.
At this time, I would like to turn the call over to your host for today, Stephen Kilmer, Investor Relations. Please go ahead.
Thank you, operator and thank you everyone for joining today's call.
I would like to advise listeners that remarks made on today's call may reflect forward-looking statements relating to such matters as BeyondSpring's clinical and preclinical research and development activities and results, regulatory and commercial plans, industry trends, market potential, collaborative initiatives and financial projections, among others. These statements are based on currently available information and management's current assumptions, expectations and projections about future events. While management believes that its assumptions, expectations and projections are reasonable in view of the currently available information, you're cautioned not to place undue reliance on these forward-looking statements. The company's actual results may differ materially from those discussed during this call for a variety of reasons, including those described in the forward-looking statements and risk factors sections of the Company's 20-F and other filings with the SEC, which are available from the Investors section of BeyondSpring's website.
Joining us on today's call is Dr. Lan Huang, Chairman and Chief Executive Officer, who will begin the call and provide a brief overview. Dr. Ramon Mohanlal, Executive Vice President of Research and Development and Chief Medical Officer, who will provide a clinical update; Richard Daly, Chief Operating Officer, who will discuss BeyondSpring's marketing and partnership strategy; and Edward Liu, Chief Financial Officer, who will provide a financial update.
It is now my pleasure to turn over the call to Dr. Huang. Lan?
Thank you, Steve. Thank you for joining the call today, ladies and gentlemen. For those of you who are new to our story, BeyondSpring is a global clinical stage biopharmaceutical company focused on developing, transforming immuno-oncology cancer therapies to address severely unmet medical need. Our lead asset, a first-in-class asset Plinabulin is in two Phase 3 global clinical programs, one as a direct anticancer agent in the treatment of non-small cell lung cancer and the other in the prevention of chemotherapy-induced neutropenia or CIN.
Since our last call, we continued to generate new data that categorized Plinabulin's unique study design and differentiated profile that further support its potential to significantly improve cancer care. In second and third line non-small cell lung cancer with EGFR wild type, which accounts for 70% to 85% of western patients, there are currently only four approved therapies available with limited survival benefit at around eight to 10 months median overall survival and certain SAEs such as severe neutropenia. Even PD-1 antibodies response rate is around 20% and only had 2.8 months median survival benefit compared to docetaxel, the standard of care in this patient population.
In CIN, the current standard prevention care is G-CSF, such as Neulasta. However, the mass